HDAC-IN-45,2421122-61-2

价格询价

品牌MedChemExpress(MCE)
产地美国
货号HY-150577
更新日期2025年12月05日

MedChemExpress LLC

品牌商

13 年钻石会员

HDAC-IN-45

CAS No. : 2421122-61-2

MCE 国际站：HDAC-IN-45

产品活性：HDAC-IN -45 (Compound 14) 是一种小分子 HDAC 抑制剂，具有抗癌活性，也可与 Y303 残基形成氢键。HDAC-IN-45 (Compound 14) 对 HDAC1、2 和 3 亚型具有显著的抑制作用， IC₅₀ 分别为 0.108、0.585 和 0.563 μM。

研究领域：Cell Cycle/DNA Damage | Epigenetics

作用靶点：HDAC

In Vitro: HDAC-IN-45 (Compound 14) suppresses the growth of triple-negative breast cancer cells MDA-MB-231 (IC₅₀ = 1.48 μM), MDA-MB-468 (IC₅₀= 0.65 μM), and liver cancer cells HepG2 (IC₅₀= 2.44 μM).
HDAC-IN-45 has equally virulent in the HDAC-sensitive cell lines (YCC11) and -resistant gastric cell lines (YCC3/7) and overcome HDACi resistance. HDAC-IN-45 has a high toxicity (IC₅₀= 0.33 μM) in three leukemic cell lines, K-562, KG-1 and THP-1.
HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC₅₀ values of 0.108, 0.585 and 0.563 μM respectively.
HDAC-IN-45 (Compound 14) can elevate acetylation level of histone H3 and expression of p21.
HDAC-IN-45 (Compound 14) exerts a dose-dependent upregulation of ac-H3K9 in MDA-MB-231 cells, triggers cell cycle arrest in G1 phase.
HDAC-IN-45 (Compound 14) exhibits a potent antitumor efficacy in xenograft mouse model.

In Vivo: HDAC-IN-45 (Compound 14) (25 mg/kg or 50mg/kg; i.p.; every day) exhibits a potent antitumor efficacy in human MDA-MB-231 breast cancer xenograft mouse model.